Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

HbA1c Testing Market Size & Growth Forecast 2026–2035, By Segments (End-use, Technology, Type of Device), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 20669| Published Date: Jul-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

HbA1c Testing Market size was more than USD 2.66 Billion in 2025 and is set to grow at a 9.2% CAGR between 2026 and 2035, reaching USD 6.41 Billion by 2035. The industry revenue for 2026 is calculated at USD 2.87 billion.

Base Year Value (2025)
USD 2.66 Billion
CAGR (2026-2035)
9.2%
Forecast Year Value (2035)
USD 6.41 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

HbA1c Testing Market Intelligence Snapshot

Regional Market Dynamics

  • North America held a 45.75% market share in 2025, supported by routine diabetes screening, established laboratory infrastructure, and consistent integration of HbA1c testing into long-term disease management.
  • Asia Pacific is projected to expand at a 10.4% CAGR as diabetes testing demand rises, healthcare access improves, and more patients enter routine monitoring and early detection programs.

Segment Momentum

  • Hospitals & Clinics held a 43.86% share in 2025 because they manage high testing volumes for diabetes diagnosis, monitoring, and treatment within established clinical care pathways.
  • High-Performance Liquid Chromatography is the fastest-growing technology as healthcare providers increasingly prioritize reliable analytical performance for ongoing diabetes management.

Market Expansion Drivers

  • Increasing global diabetes prevalence driving demand for routine HbA1c testing.
  • Adoption of point-of-care HbA1c devices improving clinical workflow efficiency.
  • Rising obesity and aging populations increasing long-term glycemic monitoring needs.

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Major companies in the HbA1c testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (United States), Tosoh Corporation (Japan), ARKRAY, Inc. (Japan), Trinity Biotech plc (Ireland), Danaher Corporation (United States), Sekisui Medical Co., Ltd. (Japan), Menarini Diagnostics S.r.l. (Italy).

Regional and Segment Outlook

North America
MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Increasing global diabetes prevalence driving demand for routine HbA1c testing

As diabetes diagnoses expand across both developed and emerging healthcare systems, routine monitoring becomes a recurring clinical requirement rather than a one-time diagnostic event, directly reinforcing market demand for the HbA1c testing market. HbA1c testing is embedded in long-term disease management because clinicians rely on it to assess average glycemic control over time, adjust treatment plans, and track adherence between visits. This creates steady testing volumes through primary care, endocrinology, hospital outpatient services, and diagnostic laboratories, while payer and provider focus on preventing complications supports more regular test utilization and broader market penetration.

Adoption of point-of-care HbA1c devices improving clinical workflow efficiency

Point-of-care adoption is driving market development in the HbA1c testing market by shifting testing closer to the patient encounter and reducing the delays associated with centralized lab processing. When clinicians receive HbA1c results during the same visit, treatment adjustments, counseling, and follow-up decisions can happen immediately, which improves workflow efficiency and makes testing more actionable in routine diabetes care. This practical advantage is influencing market adoption among physician offices, diabetes clinics, and decentralized care settings where faster turnaround supports higher testing frequency and encourages procurement of compact analyzers and consumables.

Rising obesity and aging populations increasing long-term glycemic monitoring needs

Rising obesity rates and aging populations are contributing to market size growth in the HbA1c testing market by expanding the pool of individuals at elevated risk of impaired glucose regulation, type 2 diabetes, and related metabolic conditions that require ongoing surveillance. In practice, these populations generate sustained demand not only for diagnosis support but for repeated monitoring as comorbidities, medication changes, and progression risks make glycemic control more clinically complex over time. This dynamic is supporting market expansion through greater use of HbA1c testing in chronic care pathways, especially where healthcare providers are prioritizing early intervention and long-term management over episodic assessment.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Increasing global diabetes prevalence driving demand for routine HbA1c testing 2.20% High North America, Asia Pacific High Near Term
Adoption of point-of-care HbA1c devices improving clinical workflow efficiency 2.00% High North America, Europe High Near Term
Rising obesity and aging populations increasing long-term glycemic monitoring needs 1.60% Moderate Asia Pacific, Europe High Mid Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
45.75% Market Share in 2025
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading position in 2025, accounting for a 45.75% share of the HbA1c testing market. This regional dominance is underpinned by broad clinical use of HbA1c testing in diabetes diagnosis and long-term glucose monitoring, backed by established laboratory infrastructure and routine screening practices across care settings. Market activity is reinforced by the region’s ability to integrate testing consistently into hospital laboratories, diagnostic centers, and physician-led disease management workflows, which keeps testing volumes high in everyday clinical practice.

Asia Pacific is projected to expand at a 10.4% CAGR over the forecast period, with growth in the HbA1c testing market being propelled by rising diabetes testing needs and wider adoption of diagnostic services across healthcare systems. Demand is accelerating as more patients enter formal monitoring pathways and access to testing improves beyond major urban centers, increasing the practical use of HbA1c assays in both ongoing disease management and earlier detection settings.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

Germany 🇩🇪

Standardized Diabetes Management

Germany is emphasizing HbA1c testing as a core component of structured diabetes care and disease monitoring programs. Demand is driven by the need for reliable testing platforms that support consistent treatment evaluation and patient management.

France 🇫🇷

Preventive Diabetes Care

France is encouraging wider use of HbA1c testing to strengthen preventive strategies and improve management of patients at risk of diabetes complications. Laboratories are focusing on accurate and efficient testing services that support routine monitoring.

Italy 🇮🇹

Chronic Disease Monitoring

Italy is integrating HbA1c testing more deeply into chronic disease management pathways as diabetes prevalence places greater demand on healthcare services. Providers are prioritizing dependable testing technologies that facilitate regular patient assessment and treatment adjustment.

Japan 🇯🇵

Aging Population Screening

Japan is strengthening the use of HbA1c testing to address the growing burden of age-related diabetes and metabolic disorders. Healthcare providers are integrating regular testing into preventive care and long-term disease management frameworks.

South Korea 🇰🇷

Decentralized Testing Adoption

South Korea is increasing adoption of HbA1c testing in outpatient and community settings to improve early diabetes detection and monitoring. The market favors convenient diagnostic solutions that support efficient chronic disease management programs.

United States 🇺🇸

Diabetes Monitoring Expansion

The U.S. continues to expand HbA1c testing across hospitals, diagnostic laboratories, and community care settings to improve diabetes management. Providers are prioritizing accessible and rapid testing solutions that support long-term patient monitoring and preventive care strategies.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

HbA1c Testing Market Share (%), End-use, 2025

Hospitals & Clinics
Diagnostic Laboratories
Homecare Settings

Go beyond the chart, access full insights & data tables

Request Free Sample Report
End-use Segment Analysis: Hospitals & Clinics (Largest Segment) vs Homecare Settings (Fastest-Growing Segment)

Hospitals & Clinics accounted for a 43.86% share of the HbA1c testing market in 2025, reflecting their central role in routine diabetes diagnosis, treatment monitoring, and follow-up testing. This segment maintains leadership because hospitals and clinics handle a high volume of patients who require standardized testing within established care pathways, where HbA1c results are closely tied to physician evaluation and treatment decisions. Their access to integrated diagnostic infrastructure and regular patient visits also helps sustain consistent test demand across the HbA1c testing market.

Homecare Settings are emerging as the fastest-growing segment in the HbA1c testing market as diabetes management increasingly shifts toward more convenient and patient-directed care models. Growth is being supported by the practical need for testing options that fit ongoing monitoring outside traditional clinical environments, especially for patients seeking reduced dependence on facility-based visits. Compared with hospitals and clinics, homecare settings are gaining momentum because they align more directly with the rising preference for accessible long-term disease management in everyday settings.

Technology Segment Analysis: Immunoassays (Largest Segment) vs High-Performance Liquid Chromatography (Fastest-Growing Segment)

In 2025, Immunoassays held a 37.51% share of the HbA1c testing market, supported by their broad use in routine diagnostic workflows. Their dominant position is sustained by the practical fit of immunoassays in settings that require efficient, repeatable HbA1c testing as part of regular diabetes care, making them well suited for consistent day-to-day laboratory and clinical use. This operational convenience continues to reinforce their share across the HbA1c testing market.

High-Performance Liquid Chromatography is the fastest-growing technology segment in the HbA1c testing market because demand is increasing for testing approaches that can support more refined analytical performance in diabetes assessment. Its momentum relative to alternative technologies comes from its stronger alignment with settings where result quality and method reliability are key to clinical confidence. As care providers place greater emphasis on dependable measurement in ongoing diabetes management, High-Performance Liquid Chromatography is seeing faster adoption.

Segment Sub-Segment Largest Segment Fastest Growing
End-use Hospitals & Clinics, Diagnostic Laboratories, Homecare Settings Hospitals & Clinics Homecare Settings
Technology Immunoassays, Chromatography, Enzymatic Assays, Boronate Affinity Chromatography, High-Performance Liquid Chromatography, Others Immunoassays High-Performance Liquid Chromatography
Type of Device Laboratory-based Testing Devices, Point-of-care (POC)Testing Devices Laboratory-based Testing Devices Point-of-care (POC)Testing Devices
Competitive Landscape

Competitive Landscape and Market Positioning

Top players in the HbA1c testing market:

1. Abbott Laboratories (United States)

2. F. Hoffmann-La Roche Ltd. (Switzerland)

3. Siemens Healthineers AG (Germany)

4. Bio-Rad Laboratories Inc. (United States)

5. Tosoh Corporation (Japan)

6. ARKRAY Inc. (Japan)

7. Trinity Biotech plc (Ireland)

8. Danaher Corporation (United States)

9. Sekisui Medical Co. Ltd. (Japan)

10. Menarini Diagnostics S.r.l. (Italy)

Increasing emphasis on diabetes management is accelerating innovation in the HbA1c testing market, with manufacturers introducing automated analyzers, point-of-care diagnostic systems, and high-accuracy testing technologies that improve patient monitoring and clinical workflow efficiency.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Orange Biomed Mar-25 Orange Biomed introduced an at-home HbA1c testing solution designed to enable accurate diabetes monitoring from a small blood sample. The system leverages microfluidics and single-cell analysis to improve accessibility and decentralize glycemic control tracking, supporting the shift toward patient-centric diagnostic models and expanding home-based chronic disease management capabilities.
FIND / Abbott / i-SENS / Siemens Healthineers Apr-23 FIND partnered with Abbott, i-SENS Inc, and Siemens Healthineers to provide discounted point-of-care HbA1c test kits for low- and middle-income countries. The initiative aims to improve diabetes diagnosis and monitoring accessibility in underserved regions by expanding availability of affordable diagnostic tools across decentralized healthcare settings.
LumiraDx Nov-22 LumiraDx expanded the commercial reach of its HbA1c testing platform, enabling broader adoption across multiple care settings. The system delivers rapid results for diabetes screening and monitoring, supporting improved clinical decision-making and strengthening point-of-care diagnostic capabilities in decentralized healthcare environments.
Labcorp May-22 Labcorp introduced an at-home diabetes risk testing kit using a home collection device developed by Weavr Health. The solution enhances accessibility to diagnostic services by enabling remote sample collection and supports the broader shift toward home-based screening and preventive care in diabetes management.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

HbA1c Testing Market — Custom Segments

Segment Sub-Segment
No segment data available.

HbA1c Testing Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

What is the current revenue of the HbA1c testing market?

The market valuation of the HbA1c testing is USD 2.87 billion in 2026.

What is the forecasted size of the HbA1c testing industry?

HbA1c Testing Market size is projected to grow steadily from USD 2.66 billion in 2025 to USD 6.41 billion by 2035 demonstrating a CAGR exceeding 9.2% through the forecast period (2026-2035).

How is point-of-care HbA1c testing changing procurement and clinical workflow priorities?

Point-of-care testing enables clinicians to receive results during patient visits, allowing immediate treatment decisions and improving workflow efficiency. This supports procurement of compact analyzers and consumables across physician offices and decentralized care settings.

What factors are sustaining long-term demand for HbA1c testing across healthcare systems?

Increasing diabetes prevalence, along with rising obesity and aging populations, is expanding the need for ongoing glycemic monitoring. This reinforces recurring testing across chronic disease management pathways and supports broader adoption in routine clinical practice.

Why do hospitals and clinics lead the HbA1c testing market?

Hospitals & Clinics held a 43.86% share in 2025 because they manage high testing volumes for diabetes diagnosis, monitoring, and treatment within established clinical care pathways.

Which technology segment is growing the fastest in the HbA1c testing market?

High-Performance Liquid Chromatography is the fastest-growing technology as healthcare providers increasingly prioritize reliable analytical performance for ongoing diabetes management.

Why does North America dominate the HbA1c testing market?

North America held a 45.75% market share in 2025, supported by routine diabetes screening, established laboratory infrastructure, and consistent integration of HbA1c testing into long-term disease management.

What is fueling HbA1c testing market growth in Asia Pacific?

Asia Pacific is projected to expand at a 10.4% CAGR as diabetes testing demand rises, healthcare access improves, and more patients enter routine monitoring and early detection programs.

Which companies are driving growth in the HbA1c testing landscape?

Major companies in the HbA1c testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (United States), Tosoh Corporation (Japan), ARKRAY, Inc. (Japan), Trinity Biotech plc (Ireland), Danaher Corporation (United States), Sekisui Medical Co., Ltd. (Japan), Menarini Diagnostics S.r.l. (Italy).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →